Clinicopathological features and prognosis of cytotoxic T-cell lymphoma: analysis of 134 cases.
10.3760/cma.j.cn112151-20210909-00662
- VernacularTitle:细胞毒性T细胞淋巴瘤134例临床病理学特点及预后
- Author:
Wei Hua HOU
1
;
Xiao Ge ZHOU
2
;
Jian Lan XIE
2
;
Yuan Yuan ZHENG
2
;
Yan Lin ZHANG
2
;
Xu WANG
3
Author Information
1. Department of Pathology, Pingdingshan Medical District (Former the 152 Central Hospital), the 989 Hospital of PLA Joint Logistic Support Force, Pingdingshan 467099, Henan, China.
2. Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
3. Department of Pathology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
- Publication Type:Journal Article
- MeSH:
Epstein-Barr Virus Infections/complications*;
Female;
Herpesvirus 4, Human/genetics*;
Humans;
Lymphoma, T-Cell/pathology*;
Male;
Prognosis;
Retrospective Studies
- From:
Chinese Journal of Pathology
2022;51(4):290-295
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the clinicopathological features and prognosis of cytotoxic T-cell lymphoma (CTL). Methods: The clinicopathological data of 134 CTL patients in Beijing Friendship Hospital Affiliated to Capital Medical University, the 989 Hospital of PLA Joint Logistics Support force (formerly the 152 Hospital) and the Fourth Hospital of Hebei Medical University from 2008 to 2020 were retrospectively collected. Immunophenotype, Epstein-Barr virus infection status and T cell receptor (TCR) clonality of tumor cells were assessed, and clinicopathological features and prognosis of patients were analyzed. Results: Among the 134 CTL patients, the male to female ratio was 1.7∶1.0, the median age was 49.5 years (range 3-83 years), and 100 cases (74.6%) were under 60 years old. Forty-six point nine percent of the patients (53/113) had B symptoms. Most of the patients presented with systemic superficial lymphadenopathy. According to the Ann Arbor staging system, 36.8% (39/106) of the patients were in stage Ⅰ-Ⅱ, and 63.2% (67/106) in stage Ⅲ-Ⅳ. The rate of extranodal involvement was 51.6% (66/128). Spleen was involved in 24.2% (31/128) of the cases. Morphology showed diffuse growth of abnormal lymphocytes, infiltrating and destroying normal tissue structure. Immunohistochemical staining showed that tumor cells expressed T cell antigens (CD2, CD3, CD5, and CD7), and 72.0% (77/107) of them had decreased or lost expression of one or more antigens. According to the numbers of CD4 and CD8 expression in tumor cells, 70 cases (52.2%) were grouped into CD8+>CD4+group. The expression rates of TIA-1 and granzyme B were 99.2% (119/120) and 79.8% (95/119), respectively. CD20 abnormal expression rate was 27.6% (37/134) and CD56 was negative in all cases. The median Ki-67 proliferative index was 45.0% (range 5%-80%). In situ hybridization of small RNA encoded by Epstein-Barr virus was negative. Clonal TCR gene rearrangement analysis was performed on 49 cases and was positive in all cases. Ninety-one patients were followed up for a median of 36 months (range, 1 to 240 months), and 40 of the 91 patients (44.0%) died. The twenty-three patients were in complete remission (including 13 cases with localized single extranodal mass). The 3-year and 5-year overall survival rates were 53.5% and 49.4%, respectively. Univariate analysis showed that B symptom, spleen involvement, extranodal involvement, clinical stage, CD8+>CD4+phenotype, abnormal expression of CD20 and Ki-67 proliferation index (>60%) were associated with overall survival (P<0.05). The multivariate Cox regression analyses showed that spleen involvement and CD8+>CD4+ phenotype were independent prognostic factors for overall survival in CTL patients. Conclusions: CTL are more commonly found in adult males under 60 years old, often accompanied by B symptom, with a high proportion of extranodal involvement and more CD8 positive phenotypes. Spleen involvement and CD8+>CD4+phenotype are independent predictors of CTL overall survival. Some patients with localized extranodal CTL may have a good prognosis.
